Oncopeptides AB (OM:ONCO) has had its one-year price target revised down to 2.86 kr per share, marking a 45.99% decrease from the previous estimate of 5.29 kr dated February 1, 2026. The latest targets from analysts range from a low of 2.83 kr to a high of 2.94 kr, representing a potential increase of 60.45% from the last reported closing price of 1.78 kr.
Currently, there is one fund reporting positions in Oncopeptides AB, which remains unchanged over the last quarter. Institutional ownership has decreased to 8,000 shares, reflecting a 69.56% decline for SPDR(R) Portfolio Europe ETF, which now holds 0.00% of the company after a 4.16% reduction in portfolio allocation over the quarter.
